The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: How young is "young"?

International Journal of Radiation Oncology Biology Physics

Volumn 65, Issue 5, 2006, Pages 1345-1352

  Oh, Julia L ^a   Bonnen, Mark ^a   Outlaw, Elesyia D ^a   Schechter, Naomi R ^b   Perkins, George H ^a   Strom, Eric A ^a   Babiera, Gildy ^a   Oswald, Mary Jane ^a   Allen, Pamela K ^a   Thames, Howard D ^a   Buchholz, Thomas A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast conservation therapy; Young age

Indexed keywords

BONE; CHEMOTHERAPY; HEALTH RISKS; PATIENT MONITORING; STATISTICAL METHODS; TUMORS;

BREAST CANCER; BREAST CONSERVATION THERAPY (BCT); LOCOREGIONAL RECURRENCES (LRR); MULTIVARIATE ANALYSIS; RISK FACTORS;

ONCOLOGY;

DOXORUBICIN; TAMOXIFEN; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; COMPARATIVE STUDY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; GROUPS BY AGE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TISSUE PRESERVATION; TREATMENT FAILURE; TREATMENT OUTCOME; AGE; ANALYSIS OF VARIANCE; BREAST TUMOR; CANCER STAGING; FEMALE; METHODOLOGY; MORTALITY; PATHOLOGY; REGRESSION ANALYSIS; SEGMENTAL MASTECTOMY; SURVIVAL; TUMOR RECURRENCE;

ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTORS, ESTROGEN; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33748534470     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.03.028     Document Type: Article

References (22)

1. American Cancer Society. Breast Cancer Facts and Figures, 2003-2004. Surveillance Research (2003) 3
2. Nixon A.J., Neuberg D., Hayes D.F., et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12 (1994) 888-894
3. Albain K.S., Allred D.C., and Clark G.M. Breast cancer outcome and predictors of outcome. Are there age differentials?. J Natl Cancer Inst Monogr 16 (1994) 35-42
4. Colleoni M., Rotmensz N., Robertson C., et al. Very young women (<35 years) with operable breast cancer. Features of disease at presentation. Ann Oncol 13 (2002) 273-279
5. Hankey B.F., Miller B., Curtis R., et al. Trends in breast cancer in younger women in contrast to older women. J Natl Cancer Inst Monogr 16 (1994) 7-14
6. Morrow M., and Hassett C. Breast cancer in young women. Issues in local therapy. J Natl Cancer Inst Monogr 16 (1994) 79-84
7. Borger J., Kemperman H., Hart A., et al. Risk factors in breast-conservation therapy. J Clin Oncol 12 (1994) 653-660
8. Foxcroft L.M., Evans E.B., and Porter A.J. The diagnosis of breast cancer in women younger than 40. Breast 13 (2004) 297-306
9. Kim S.H., Simkovich-Heerdt A., Tran K.N., et al. Women 35 years of age or younger have higher local-regional relapse rates after undergoing breast conservation therapy. J Am Coll Surg 187 (1988) 1-8
10. Elkhuizen P.H., van de Vijver M.J., Hermans J., et al. Local recurrence after breast-conserving therapy for invasive breast cancer. High incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys 40 (1998) 859-867
11. Lawless J.F. Statistical models and methods for lifetime data (1982), John Wiley and Sons, New York
12. Zhou P., and Recht A. Young age and outcome for women with early-stage invasive breast carcinoma. Cancer 101 (2004) 1264-1274
13. de la Rochefordiere A., Asselain B., Campana F., et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 341 (1993) 1039-1043
14. Fisher B., Jeong J.H., Anderson S., et al. Twenty-five year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347 (2004) 567-575
15. Veronesi U., Salvadori B., Luini A., et al. Conservative treatment of early breast cancer. Long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy. Ann Surg 211 (1990) 250-259
16. Solin L.J., Fowble B., Schultz D.J., et al. Age as a prognostic factor for patients treated with definitive irradiation for early stage breast cancer. Int J Radiat Oncol Biol Phys 16 (1989) 373-381
17. Kurtz J.M., Jacquemier J., Luini A., et al. Risk factors for breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapy. Cancer 65 (1990) 1867-1878
18. Matthews R.H., McNeese M.D., Montague E.D., et al. Prognostic implications of age in breast cancer patients treated with tumorectomy and irradiation or with mastectomy. Int J Radiat Oncol Biol Phys 12 (1998) 659-663
19. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival. An overview of the randomised trials. Lancet 365 (2005) 1687-1717
20. Nolvadex (Tamoxifen Citrate) brochure by AstraZeneca. Available at: www.astrazeneca-us.com/pi/Nolvadex.pdf.
21. Goldhirsch A., Gelber R.D., Yothers G., et al. Adjuvant therapy for very young women with breast cancer. Need for tailored treatments. J Natl Cancer Inst Monogr 30 (2001) 44-51
22. Dellapasqua S., Colleoni M., Gelber R., et al. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 23 (2005) 1736-1750